Randomized phase III trial of cisplatin plus paclitaxel with and without NCI-supplied bevacizumab (NSC #704865, IND #7921) versus the non-platinum doublet, topotecan plus paclitaxel, with and without NCI-supplied bevacizumab, in stage IVB, recurrent or persistent carcinoma of the cervix

eagle-i ID

Resource Type

Properties

1. ClinicalTrials.gov url

   http://www.clinicaltrials.gov/ct2/show/NCT00803062?term=GOG-0240&rank=1

2. Intervention

   Cisplatin

3. Intervention

   Paclitaxel

4. Intervention

   Topotecan hydrochloride

5. Intervention

   Bevacizumab

6. Additional Topic(s)

   Antineoplastic combined chemotherapy protocols

7. Resource Description

   Purpose: It is not yet known whether paclitaxel is more effective when given together with cisplatin or topotecan with or without bevacizumab in treating patients with cervical cancer. This randomized phase III trial is studying the side effects of paclitaxel when given together with cisplatin or topotecan with or without bevacizumab and to compare how well they work in treating patients with stage IVB, recurrent, or persistent cervical cancer.

8. Contact

   Berenberg, Jeffrey

9. PI

   Berenberg, Jeffrey

10. Topic

    cervix carcinoma

11. Study Population

    Females age 18 and older with measurable disease, no primary brain tumor, brain metastases, or spinal cord metastases, no previous bevacizumab, at least 6 weeks since chemotherapy with radiation therapy, at least 3 weeks since radiation therapy, and more than 4 weeks since surgery or open biopsy.

12. Website(s)

    http://www.cancer.gov/clinicaltrials/search/view?cdrid=628746&version=healthprofessional

13. Funded by

    Gynecologic Oncology Group

14. Phase

    Phase 3 clinical trial

15. Performed by

    Clinical Protocol & Data Management Shared Resource